Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes

被引:0
|
作者
De Luca, A [1 ]
Vendittelli, M
Boldini, F
Di Giambenedetto, S
Trotta, MP
Cingolani, A
Bacarelli, A
Gori, C
Perno, CF
Antinori, A
Ulivi, G
机构
[1] Univ Cattolica Sacro Cuore, Inst Clin Infect Dis, I-00168 Rome, Italy
[2] Univ Roma La Sapienza, Dept Comp & Syst Sci, Rome, Italy
[3] IRCCS, Natl Inst Infect Dis, Rome, Italy
[4] Univ Roma Tor Vergata, Dept Expt Med, Rome, Italy
[5] Univ Roma Tor Vergata, Dept Comp Sci & Automat, Rome, Italy
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To evaluate whether fuzzy operators can be usefully applied to the interpretation of genotypic HIV-1 drug resistance by experts, and to improve the prediction of salvage therapy outcome by adapting interpretation rules of genotypic resistance on the basis of their association with virological response data. Methods: We used a clinical dataset of 231 patients failing highly active antiretroviral therapy (HAART) and starting salvage therapy with baseline resistance genotyping and virological outcomes after 3 and 6 months. A set of rules predicting genotypic resistance was initially derived from an expert (ADL). Rules were implemented using a fuzzy logic approach and the virological outcomes dataset used for the training phase. The resulting algorithm was validated using a separate set of 184 selected patients by correlating the resulting predicted activity with observed virological response at 3 months. For comparison, the expert systems from the drug resistance group of the Agence Nationale de Recherches sur le SIDA (ANRS-AC11) and the algorithm from the Stanford's HIV drug resistance database (Stanford HIVdb) were evaluated on the same set. Results: The starting algorithm had a correlation with virological outcomes of R-2 = 0.06 (P = 0.0001). After the training phase the correlation with virological outcomes increased to R-2 = 0.19 (p < 0.000001). In the validation set of patients, the activity of the salvage regimen predicted by the fuzzy algorithm was the only variable independently predictive of the 3-month viral load change even after adjusting by the activity predicted by the two expert systems and baseline viral load (for each 10% salvage regimen's activity increase, mean HIV RNA change from baseline: -0.27 log(10) copies/ml; 95% CI -0.39, -0.15). Conclusion: Using fuzzy operators in a virological outcomes training database to implement a rules-based algorithm for genotypic resistance interpretation, significant improvements of outcomes prediction were obtained. The resulting algorithm showed an independent predictive capability of virological outcomes over that of two rules-based interpretation algorithms made by experts. Although the system was trained and validated on a limited number of cases, the approach deserves further evaluation.
引用
收藏
页码:583 / 593
页数:11
相关论文
共 50 条
  • [31] Treatment history adds little or no predictive value to HIV-1 genotypic resistance interpretation during highly active antiretroviral therapy failure for subsequent virological outcome: different value according to interpretation system and salvage treatment
    De Luca, A
    Giambenedetto, S
    Baldini, F
    Rizzo, MG
    Cingolani, A
    Trotta, MP
    Giannella, S
    Narciso, P
    Perno, CF
    Ulivi, G
    Antinori, A
    ANTIVIRAL THERAPY, 2002, 7 : S100 - S100
  • [32] Construction of a drug candidate screening system based on HIV-1 Rev/RRE functional activity
    Zemskaia, A. S.
    Sherman, D. K.
    Solyev, P. N.
    Valuev-Elliston, V. T.
    FEBS OPEN BIO, 2024, 14 : 227 - 228
  • [33] Clinical Evaluation of a Novel NGS-based HIV-1 Drug Resistance Monitoring Test
    Rakhmanaliev, E.
    Chantratita, W.
    Nimitsuntiwong, P.
    Wathtphan, C.
    Passomsub, E.
    Luo, R.
    Ariyaratne, P.
    Lee, C.
    Michel, G.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (02): : S18 - S19
  • [34] Virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based treatment in clinical practice
    Armenia, D.
    Forbici, F.
    Bertoli, A.
    Berno, G.
    Malagnino, V.
    Gagliardini, R.
    Borghi, V.
    Gennari, W.
    Cicalini, S.
    Buonomini, A.
    Teti, E.
    Latini, A.
    Sarmati, L.
    Mussini, C.
    Andreoni, M.
    Antinori, A.
    Perno, C. F.
    Ceccherini-Silberstein, F.
    Santoro, M. M.
    HIV MEDICINE, 2021, 22 : 26 - 28
  • [35] Genotypic HIV-1 Drug Resistance Among Patients Failing Tenofovir-Based First-Line HAART in South India
    Dinesha, Thongadi Ramesh
    Gomathi, Selvamurthi
    Boobalan, Jayaseelan
    Sivamalar, Sathasivam
    Solomon, Sunil S.
    Pradeep, Ambrose
    Poongulali, Selvamuthu
    Solomon, Suniti
    Balakrishnan, Pachamuthu
    Saravanan, Shanmugam
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (12) : 1234 - 1236
  • [36] Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study
    Hamers, Raph L.
    Schuurman, Rob
    Sigaloff, Kim C. E.
    Wallis, Carole L.
    Kityo, Cissy
    Siwale, Margaret
    Mandaliya, Kishor
    Ive, Prudence
    Botes, Mariette E.
    Wellington, Maureen
    Osibogun, Akin
    Wit, Ferdinand W.
    van Vugt, Michele
    Stevens, Wendy S.
    de Wit, Tobias F. Rinke
    LANCET INFECTIOUS DISEASES, 2012, 12 (04): : 307 - 317
  • [37] A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: The resistance and dosage adapted regimens (RADAR) study
    Torti, C
    Quiros-Roldan, E
    Regazzi, M
    De Luca, A
    Mazzotta, F
    Antinori, A
    Ladisa, N
    Micheli, V
    Orani, A
    Patroni, A
    Villani, P
    Lo Caputo, S
    Moretti, F
    Di Giambenedetto, S
    Castelnuovo, F
    Maggi, P
    Tinelli, C
    Carosi, G
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (12) : 1828 - 1836
  • [38] Development, Validation and Clinical Evaluation of a Low Cost In-House HIV-1 Drug Resistance Genotyping Assay for Indian Patients
    Acharya, Arpan
    Vaniawala, Salil
    Shah, Parth
    Misra, Rabindra Nath
    Wani, Minal
    Mukhopadhyaya, Pratap N.
    PLOS ONE, 2014, 9 (08):
  • [39] Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients
    Vergne, L
    Snoeck, J
    Aghokeng, A
    Maes, B
    Valea, D
    Delaporte, E
    Vandamme, AM
    Peeters, M
    Van Laethem, K
    FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2006, 46 (01): : 53 - 62
  • [40] Clinical cut-offs for HIV-1 phenotypic resistance estimates: Update based on recent pivotal clinical trial data and a revised approach to viral mixtures
    Winters, Bart
    Van Craenenbroeck, Elke
    Van der Borght, Koen
    Lecocq, Pierre
    Villacian, Jorge
    Bacheler, Lee
    JOURNAL OF VIROLOGICAL METHODS, 2009, 162 (1-2) : 101 - 108